<div id="readability-page-1"><p>Tuhura Biosciences, Inc. (<span>HURA</span>) has disclosed a new risk, in the Debt &amp; Financing category.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>The analyst notes that Tuhura Biosciences, Inc.’s revolving credit facility with Parkview Holdings One, LLC, secured by substantially all of its assets and bearing a 12% interest rate, introduces significant leverage and covenant constraints that could restrict strategic and operational flexibility. In addition, Parkview’s ability to accelerate the debt, foreclose on assets, or convert outstanding obligations into equity at a fixed price in certain default scenarios creates both going‑concern risk and the potential for substantial shareholder dilution.</p> <p>The concurrent royalty agreement on products using Tuhura’s IFx‑2.0 technology further diverts future cash flows, reducing net commercialization proceeds and potentially straining liquidity alongside debt service obligations. Together, these arrangements could impair Tuhura’s capacity to fund growth initiatives, withstand slower‑than‑expected commercialization, or avoid distressed financing or insolvency outcomes if covenant breaches or adverse operating results occur.</p> <p>Overall, Wall Street has a Strong Buy <span>consensus rating</span> on HURA stock based on 3 Buys.</p> <p>To learn more about Tuhura Biosciences, Inc.’s risk factors, <span>click here</span>.</p></div>

HURA

LABU

SBIO

<p>Tuhura Biosciences, Inc. (HURA) faces heightened liquidity and dilution risks due to a new revolving credit facility with Parkview Holdings, secured by its assets and carrying a 12% interest rate. This introduces leverage and covenant constraints, potentially limiting operational flexibility and increasing the risk of shareholder dilution. Additionally, a royalty agreement on its IFx-2.0 technology may strain liquidity and hinder growth funding. Despite these risks, HURA stock holds a Strong Buy consensus rating from analysts.</p>

Tip Ranks

TuHURA Biosciences

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Leverage, Covenants and Royalty Drain: Why Tuhura Biosciences’ Parkview Credit Deal Heightens Liquidity and Dilution Risks